Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The ONWARD3 data indicates that 54% of patients treated with envudeucitinib achieved complete skin clearance after 48 weeks. The treatment demonstrated a favorable long-term safety and tolerability profile consistent with earlier findings. The company is preparing to submit a New Drug Application to the FDA in the fourth quarter.
Market Sentiment Analysis
POSITIVE FACTORS
54% of patients achieved complete skin clearance (PASI 100).
Long-term safety and tolerability profile is favorable.
Data may set a new standard for plaque psoriasis treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+122%
120-day peak, hindsight
Typical move
1.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
envudeucitinib
Phase 3 · Plaque Psoriasis
Full Press Release Details
– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long - term safety and tolerability profile remained consistent with previously reported data – – On track to submit a New Drug Application to FDA in 4Q
Frequently Asked Questions
What percentage of patients achieved PASI 100?
54% of patients reached complete skin clearance (PASI 100) after 48 weeks.
What is the safety profile of envudeucitinib?
The long-term safety and tolerability profile remains favorable and consistent.
When will the FDA submission occur?
The New Drug Application is on track to be submitted in the fourth quarter.